DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for chronic myelogenous leukemia — screening already-approved drugs against its 44-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleChronic myelogenous leukemia maps to a 44-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for chronic myelogenous leukemia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
NRAS proto-oncogene, GTPase (NRAS) — NRAS is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gdpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6ZIO · 1.55 Å · ligand GUANOSINE-5'-DIPHOSPHATE (GDP). Experimental structure, not a prediction.
What the evidence adds up to
The 1994 review of chronic leukaemias notes that clinical manifestations and treatment strategies vary widely, and that in some cases withholding treatment entirely may be more appropriate than immediate aggressive therapy. A 1998 review describes chronic myelogenous leukaemia (CML) as one of several distinct clinicopathologic entities that respond to specific therapies, and states that identifying specific molecular lesions helps explain the molecular mechanisms contributing to leukemogenesis. Neither review provides survival data, response rates, or sample sizes.
A 2021 review of BCR-ABL-negative atypical chronic myeloid leukaemia, a rare disorder classified among myelodysplastic/myelodysplastic/myeloproliferative diseases, focuses on molecular pathogenesis and emerging targeted therapies. It does not report clinical outcomes. A 2015 review of relapsed and refractory acute myeloid leukaemia (AML) states that no currently available treatment has demonstrated consistent efficacy in terms of salvage therapy or long-term survival, and that most patients succumb despite aggressive strategies. That review discusses emerging targeted molecular therapies, novel cytotoxics, and immune-based approaches, but gives no concrete numbers.
No abstract provides evidence for any drug repurposing in chronic myelogenous leukaemia. The 1994 and 1998 reviews are general overviews without trial data. The 2021 and 2015 reviews concern related but distinct diseases (atypical CML and relapsed/refractory AML) and offer no quantitative results. What is missing for any drug-repurposing effort in CML is prospective clinical trial data with reported response rates and survival, adequate patient stratification, and dedicated funding for such studies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
CA A Cancer Journal for Clinicians · 1994 · 13 citations · open access
Chronic leukemias
AbstractChronic leukemias include a broad spectrum of disorders generally characterized by uncontrolled proliferation of mature, differentiated cells of the hematopoietic system. Clinical manifestations and treatment strategies vary widely among the disorders. In some cases, immediate aggressive treatment is required; while in others, it is more appropriate to withhold immediate treatment and perhaps not treat at all. This article reviews the pathologic features, clinical characteristics, and treatment of chronic leukemias.
Frontiers in Oncology · 2021 · 10 citations · open access
Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
AbstractAtypical chronic myeloid leukemia is a rare disease whose pathogenesis has long been debated. It currently belongs to the group of myelodysplastic/myeloproliferative disorders. In this review, an overview on the current knowledge about diagnosis, prognosis, and genetics is presented, with a major focus on the recent molecular findings. We describe here the molecular pathogenesis of the disease, focusing on the mechanisms of action of the main mutations as well as on gene expression profiling. We also present the treatment options focusing on emerging targeted therapies.
AbstractThe acute and chronic leukemias arise from the uncontrolled clonal expansion of hematopoietic progenitor cells blocked in differentiation. The different types of leukemia represent distinct clinicopathologic entities that have characteristic biological and clinical properties and respond to specific therapies. The identification of specific molecular lesions helps us to understand the molecular mechanisms that contribute to leukemogenesis. Here we review the epidemiology, clinical features, and molecular genetics of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), and chronic lymphocytic leukemia (CLL).
Ostre białaczki szpikowe – leczenie postaci nawrotowych i opornych
AbstractRelapsed and refractory acute myeloid leukemia (AML) is defined by clinical and biologic features that predict their poor response to therapy. Despite even the most aggressive and well-developed strategies for treatment, most patients succumb to the disease. No currently available treatment has demonstrated consistent efficacy in terms of salvage therapy or long-term survival in this group of patients. This review will discuss some of the emerging strategies: targeted molecular therapies, novel cytotoxics, and immune-based therapies to treat relapsed and refractory AML patients.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
